Larimar Therapeutics GAAP EPS of -$0.45

Stock Information for Larimar Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Larimar Therapeutics Inc.

Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program
Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia
Larimar Therapeutics Reports First Quarter 2025 Financial Results
Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia
Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia
Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.